Physician profile
Brian Hyett
NPI 1972722015
$184,763.21
in general payments reported to CMS, 2019-2025
35 companies · $55K in 2025
The $55K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $4,279 · 2021: $17K · 2022: $23K · 2023: $27K · 2024: $13K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $49K · Consulting Fee: $31K · Travel and Lodging: $9,780 · Food and Beverage: $4,709 · Education: $86.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,407.64 |
| Consulting Fee | $30,840.20 |
| Travel and Lodging | $9,780.33 |
| Food and Beverage | $4,708.67 |
| Education | $86.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $127,581.26 | 2019-2025 | |
| Celltrion USA INC. | $30,978.71 | 2024-2025 | Zymfentra, Vegzelma |
| Janssen Scientific Affairs, LLC | $12,994.36 | 2021-2022 | |
| Janssen Biotech, INC. | $9,403.21 | 2019-2025 | Tremfya, Stelara, Axert |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $726.80 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $489.55 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $303.14 | 2019-2025 | |
| Gilead Sciences, INC. | $267.02 | 2019-2025 | Livdelzi |
| Genzyme Corporation | $227.27 | 2023-2025 | |
| Covidien Lp | $196.27 | 2019 | |
| Boston Scientific Corporation | $177.88 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $156.61 | 2019-2024 | Rebyota, Clenpiq |
| Intercept Pharmaceuticals, INC. | $126.35 | 2019-2024 | Ocaliva |
| Allergan, INC. | $123.25 | 2019 | |
| Qol Medical, LLC | $102.09 | 2024-2025 | Sucraid, Sucraid |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $96.66 | 2019-2024 | Dificid |
| Organon LLC | $73.75 | 2023-2025 | Renflexis, Hadlima |
| Ironwood Pharmaceuticals, INC | $68.10 | 2020-2022 | |
| Ucb, INC. | $61.93 | 2019 | |
| Daiichi Sankyo INC. | $59.02 | 2020-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $57.30 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $57.12 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.53 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $56.31 | 2019-2020 | |
| Ardelyx, INC. | $55.34 | 2023-2024 | Ibsrela |
| Amgen INC. | $46.71 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $41.58 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $39.99 | 2024 | Dupixent |
| Celgene Corporation | $30.73 | 2022 | |
| Lundbeck LLC | $25.41 | 2023 | Vyepti |
| Shire North American Group INC | $23.90 | 2019 | |
| Endo Pharmaceuticals INC. | $21.23 | 2019 | |
| Biodelivery Sciences International, INC. | $13.41 | 2021 | |
| Medtronic, INC. | $12.45 | 2021 | |
| Ethicon US, LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hyett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.